CV-6209
Based on 1 Customer Validation
CV-6209 is a potent antagonist of platelet activating factor (PAF). CV-6209 inhibits the PAF-induced aggregation of rabbit and human platelets, with IC50s of 75 nM and 170 nM, respectively. CV-6209 can inhibit PAF-induced hypotension in rats.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 98.0%
- CAS. Nr.: 100488-87-7
- Formel: C34H60ClN3O6
- Molecular Weight:642.31
-
Speicherung:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-108634
ApafantPAF Receptor Antagonist -
HY-17497
Acebutololβ1 Adrenergic Receptor Antagonist -
HY-108635
C16-PAFPAFR Activator -
HY-137257
Carbamyl-PAFPAF receptor Agonist -
HY-106837
IsrapafantPAF Antagonist -
HY-108908A
ModipafantPAF Antagonist -
HY-W011651R
Carbutamide (Standard)Anti-diabetic Drug -
HY-W011651
CarbutamideAnti-diabetic Drug -
HY-N10663
KadsurenonePlatelet-activating Factor Antagonist -
HY-142986
Dlin-MeOHDrug Intermediate -
HY-114745
MoTPPAF Receptor Antagonist -
HY-19121A
TCV-309 chloridePAF Antagonist
Biologische Aktivität
Beschreibung
IC50 & Target
platelet activating factor (PAF)[1]
In Vitro
CV-6209 inhibits [3H]serotonin release from rabbit platelets stimulated with PAF (30 nM)[1].
CV-6209 has little action on platelet aggregation induced by arachidonic acid, ADP, or collagen[1].
CV-6209 (0.2-2 μM; pretreated for 30 min) inhibits PAF-induced MC degranulation in both LAD2 and hLMCs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
In Vivo
CV-6209 (66 μg; i.v.) reduces asparaginase-induced hypersensitivity compared with nonpretreated, sensitized mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 100488-87-7
-
Appearance Solid
-
Molecular Weight 642.31
-
Formel C34H60ClN3O6
-
Color Off-white to light yellow
-
SMILES
CC[N+]1=CC=CC=C1CN(C(C)=O)C(OCC(OC)COC(NCCCCCCCCCCCCCCCCCC)=O)=O.[Cl-]
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 100 mg/mL (155.69 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Reinheit & Dokumentation
-
Data Sheet (267 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Terashita Z, et, al. CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo. J Pharmacol Exp Ther. 1987 Jul;242(1):263-8. [Content Brief]
[2]. Munoz-Cano R, et, al. Effects of Rupatadine on Platelet- Activating Factor-Induced Human Mast Cell Degranulation Compared With Desloratadine and Levocetirizine (The MASPAF Study). J Investig Allergol Clin Immunol. 2017;27(3):161-168. [Content Brief]
[3]. Fernande CA, et, al. Effect of premedications in a murine model of asparaginase hypersensitivity. J Pharmacol Exp Ther. 2015 Mar;352(3):541-51. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.5569 mL | 7.7844 mL | 15.5688 mL | 38.9220 mL |
| 5 mM | 0.3114 mL | 1.5569 mL | 3.1138 mL | 7.7844 mL | |
| 10 mM | 0.1557 mL | 0.7784 mL | 1.5569 mL | 3.8922 mL | |
| 15 mM | 0.1038 mL | 0.5190 mL | 1.0379 mL | 2.5948 mL | |
| 20 mM | 0.0778 mL | 0.3892 mL | 0.7784 mL | 1.9461 mL | |
| 25 mM | 0.0623 mL | 0.3114 mL | 0.6228 mL | 1.5569 mL | |
| 30 mM | 0.0519 mL | 0.2595 mL | 0.5190 mL | 1.2974 mL | |
| 40 mM | 0.0389 mL | 0.1946 mL | 0.3892 mL | 0.9731 mL | |
| 50 mM | 0.0311 mL | 0.1557 mL | 0.3114 mL | 0.7784 mL | |
| 60 mM | 0.0259 mL | 0.1297 mL | 0.2595 mL | 0.6487 mL | |
| 80 mM | 0.0195 mL | 0.0973 mL | 0.1946 mL | 0.4865 mL | |
| 100 mM | 0.0156 mL | 0.0778 mL | 0.1557 mL | 0.3892 mL |
CV-6209 Related Classifications
HY-109897 Related Classifications
Powered by Bioz